Cooper Companies Reaches New 52-Week High (COO)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

NEW YORK ( TheStreet) -- Cooper Companies (NYSE: COO) hit a new 52-week high Friday as it is currently trading at $94.81, above its previous 52-week high of $89.31 with 500,715 shares traded as of 10:05 a.m. ET. Average volume has been 457,600 shares over the past 30 days.

Cooper Companies has a market cap of $4.07 billion and is part of the health care sector and health services industry. Shares are up 22% year to date as of the close of trading on Thursday.

The Cooper Companies, Inc. engages in the provision of medical devices for healthcare professionals worldwide. The company has a P/E ratio of 19.6, below the average health services industry P/E ratio of 20.2 and above the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Cooper Companies as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth, compelling growth in net income, reasonable valuation levels and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. You can view the full Cooper Companies Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge! Free download now.
null

If you liked this article you might like

Teva Nailed With S&P Downgrade

Teva Nailed With S&P Downgrade

7 Investment Themes You Can't Afford to Miss for 2018

7 Investment Themes You Can't Afford to Miss for 2018

Teva Still Has Big Problems It Must Deal With in 2018

Teva Still Has Big Problems It Must Deal With in 2018

Teva Closes Higher as Generic Drugmaker Announces Massive Layoffs, Asset Sales

Teva Closes Higher as Generic Drugmaker Announces Massive Layoffs, Asset Sales

The 60-Year-Old Gold Bug and the 25-Year-Old Bitcoin Fan Are Alike: Market Recon

The 60-Year-Old Gold Bug and the 25-Year-Old Bitcoin Fan Are Alike: Market Recon